UCL ENTERPRISE

Spotlight

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Views

By Stephen Caddick, Vice-Provost (Enterprise) at UCLTHE AWARD of the Nobel Prize in Physiology or Medicine this week to London-based professor John O’Keefe, along with his colleagues Moser and Moser, is well-deserved recognition for truly ground-breaking science – science which, in time, could have profound ramifications for the way we understand and treat neurological diseases like Alzheimer’s.More...

The recent success of Imperial College in realising £10m cash in exchange for a 10 per cent share holding in Imperial Innovations shows the continued market interest in the commercialisation of university research (report, 24 June).More...

[Re: Why Britain’s scientists are failing at business, Friday]
Tim Farron is right to highlight some of the challenges facing all
entrepreneurs in this country, but the idea that Britain’s scientific
community is failing at business is simply not accurate.More...

The recent sale of London tech start-up DeepMind to Google for a reported £400m is the latest in a series of deals highlighting the ever-increasing entrepreneurial spirit of Britain's scientists - and does much to dispel the myth that the UK is good at science but poor at innovation and enterprise.More...